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sociated with treatment and productivity loss over a one year period at vaccine
steady state (i.e. when all women are vaccinated), current vs. future burden assum-
ing 95% vaccine coverage. The MR incidence data on abnormal PAP and CINs were
extrapolated from the relative proportion of abnormal PAP, precancerous lesions
and CC previously published. Vaccination effectiveness was based on clinical trial
data and HPV distribution for Russia and Eastern Europe. Medical costs were esti-
mated from resources used and listed Russian price. Indirect costs include unpaid
taxes, illness allowance and regional GDP foregone. No discount was applied. Sen-
sitivity analyses were conducted on main parameters (number of lesions, vaccine
effectiveness, costs). RESULTS: Vaccination with the bivalent HPV vaccine in the
MR was estimated to prevent 13,737 abnormal PAP (112.6 m.rub.), 11,750 CIN1 (296.1
m.rub.), 4,222 CIN2/3 (259.3 m.rub.), 504 CC (98.9 m.rub.), 199 cases of lifelong dis-
ability (44.6 m.rub.) and 276 cases of CC deaths annually. Total cost offsets could
amount to 811.6 m.rub. (664.8 m.rub. treatment cost only) representing 2.5x annual
cost of vaccinating one cohort of 12 year-old girls (328.9 m.rub.) (2.0x vs. treatment
cost only). The benefit-to-cost ratio (cost offset/vaccination cost) ranged from 1.8 to
3.1 over the sensitivity analyses. CONCLUSIONS: Implementation of HPV vaccina-
tion in the MR could significantly decrease cervical HPV-infection disease-related
burden. The cost of vaccination, at steady state, could be fully compensated by the
cost offset.
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OBJECTIVES:To investigate the extent to which using the most efficacious first-line
therapy to manage advanced non-small cell lung cancer (NSCLC) based on patients’
EGFR mutation status has clinical, economic, and quality of life (QoL) benefits from
diagnosis to death. METHODS: A deterministic cost-consequence model was de-
veloped to investigate alternative diagnostic and treatment strategies across mul-
tiple treatment lines in advanced NSCLC. Cost (drug and other treatment-related),
resource use, clinical, and QoL data were included. Cost and resource use data were
derived from the Dutch National Formulary, market research studies and expert
opinion. Clinical and QoL data – including progression-free survival (PFS) – were
derived from published studies and expert opinion. RESULTS:Different testing and
treatment strategies were modelled in a hypothetical population of 1,000,000 indi-
viduals. 498 patients presented with stage III/IV NSCLC. In the base-case (no EGFR
mutation testing) all patients received first-line doublet chemotherapy followed by
second-line docetaxel (50%) or best supportive care (50%). Total median PFS in the
population was 246.00 years (5.93 months per patient). Total healthcare costs, in-
cluding adverse event (AE) management, were €11,801,371 (€23,698 per patient).
EGFR mutation testing all patients identified 60 patients as EGFR mutation-posi-
tive. First-line treatments were assigned based on mutation status (EGFR muta-
tion-positive patients received gefitinib followed by second-line docetaxel, all oth-
ers were treated as in the base-case strategy). Compared with the base-case
strategy there was an 11.8% increase in total PFS (0.70 months per patient). Second-
line PFS increased 12.0%. Additionally, fewer AEs (anaemia, diarrhoea, dyspnoea,
febrile neutropenia, neurotoxicity and vomiting) and improved QoL were seen.
Excluding testing costs, total healthcare costs increased 17.4%. CONCLUSIONS:
Strategies where patients were appropriately treated based on EGFR mutation sta-
tus increased clinical and QoL benefits at relatively low incremental cost, com-
pared to strategies where patients were not tested or were treated sub-optimally.
Benefits extended beyond first-line treatment.
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OBJECTIVES: Two human papillomavirus (HPV) vaccines are available worldwide:
a bivalent vaccine (BV) targeting oncogenic high-risk HPV-16/18 and a quadrivalent
vaccine (QV) targeting both high-risk HPV-16/18 and low-risk HPV-6/11. Based on
data in their respective trials, BV is likely to have higher efficacy against non-
vaccine oncogenic HPV-types (cross protection). QV has an effect against genital
warts (GW). The potential effect of both vaccines in Thailand on cervical intraepi-
thelial neoplasia grade 1-3 (CIN1-3), GW, cervical cancer (CC) and related treatment
costs was investigated. METHODS: A static model estimated the above outcomes
over a one-year period at steady state versus the current situation. Costs were
assessed from a health care payer’s perspective. Epidemiological and cost data
were obtained from published sources; efficacy figures were based on the latest
clinical trial results from each vaccine and region-specific HPV distribution among
lesions (local data was used where possible). Sensitivity analyses were conducted
on all input data, such as with scenarios where the incidence and costs of treating
GW were varied. RESULTS: BV was projected to avert 9394 cases of CC annually. BV
potentially would result in an additional reduction of 5470 CIN1, 5177 CIN2/3 and
1113 CC cases annually compared with QV, while QV potentially would prevent an
additional 125,957 GW cases annually. The additional cost saved with BV was es-
timated at THB 356 million annually compared with QV. Sensitivity analyses report
additional cost-savings for the BV compared with QV under all scenarios.
CONCLUSIONS: The level of cross protection of BV potentially would allow for an
additional reduction in CC and HPV-related morbidity compared to QV; under our
model, this resulted in cost averted that offset the economic benefit QV will have in
preventing GW in Thailand.
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OBJECTIVES: Sunitinib is an oral multitargeted tyrosine kinase inhibitor approved
in Europe in 2010 for use in well-differentiated pancreatic neuroendocrine tumors
(pNET) that have spread or cannot be removed with surgery. This study evaluated
the cost-effectiveness of sunitinib  best supportive/palliative care (BSC) com-
pared to placebo  BSC in Portuguese patients. METHODS: A Markov model was
adapted to predict life-years (LY) and associated costs (€) of pNET patients’ treat-
ment over lifetime in Portugal. The model tracks transitions of patients between
three health states: progression free, post-progression and death. Transition prob-
abilities between health states and adverse events probabilities were based on
published results from the phase III pNET trial of sunitinib. BSC overall survival (OS)
probabilities were adjusted for crossover with a rank preserving structural failure
time (RPSFT) statistical analysis. Resource use was elicited through a panel of five
Portuguese experts with extensive clinical experience. Subsequent treatments are
not included given the lack of efficacy evidence. Adverse events treatment costs
and unit costs were extracted from Portuguese literature and official sources. A
National Health Service perspective was adopted and both costs and effectiveness
were discounted at 5%. RESULTS: Average cost per patient for sunitinib BSC and
placebo  BSC treatment were 54,215€ and 10,239€ respectively, while the average
effectiveness gained with sunitinib was 1.83LY. This resulted in an incremental
cost-effectiveness ratio (ICER) of 24,035€/LY. While the application of the RPSFT
method may have some limitations and therefore provide uncertainty regarding
the true OS benefit, the intent-to-treat classic analysis that does not correct for the
confounding effect of crossover generated an ICER of 34,387€/LY. CONCLUSIONS:
Compared with BSC, sunitinib treatment in patients with advanced or metastatic
unresectable pNET improve effectiveness in terms of life-years gained and is cost-
effective by the commonly used threshold in Portugal for assessment of new health
technologies.
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OBJECTIVES: To assess, from a UK NHS perspective, the cost-effectiveness of the
addition of rituximab (R) to selected chemotherapies: CVP (cyclophosphamide, vin-
cristine and prednisolone); CHOP (cyclophosphamide, doxorubicin, vincristine and
prednisolone) and MCP (mitoxantrone, chlorambucil and prednisolone) in the first-
line treatment of follicular lymphoma. METHODS: A patient level simulation
model was developed with four mutually exclusive and exhaustive health states:
progression free survival on first line treatment (the starting state); progression
free survival on second line treatment (PFS2); progression; and death (an absorbing
state). First-line treatment consisted of chemotherapy or R-chemotherapy. Pa-
tients relapsing before death move into PFS2 and are assumed to receive second-
line treatment dependent on initial treatment and time of relapse. After progres-
sion, patients enter the progression state where they reside until death. The model
horizon was 25 years with costs and benefits discounted at 3.5%. Separate analyses
were undertaken assuming rituximab maintenance for patients who responded to
R-chemotherapy in first-line induction. Evidence from phase III trial were used
when possible, however due to data limitations, assumptions were necessary
which increases the uncertainty in the results. RESULTS: The estimated Incremen-
tal Cost-Effectiveness Ratios (ICERs) for the addition of rituximab to CVP, CHOP and
MCP were £7,720, £10,834 and £9,316 per QALY gained respectively assuming no
first-line rituximab maintenance. The ICERs increased to £14,959, £21,687 and
£20,493 per QALY gained respectively when maintenance treatment was assumed.
The ICER was sensitive to assumptions regarding the choice of parametric distri-
bution to model the effectiveness of first-line treatment, the maximum time a
patient can remain progression-free and potential resistance to rituximab, with the
most favourable (unfavourable) ICER being approximately £4,000 (£61,000) per
QALY gained. CONCLUSIONS: The addition of rituximab to CVP, CHOP and MCP is
expected to fall below a cost per QALY gained of £25,000 regardless of the assump-
tion on maintenance.
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OBJECTIVES: The analysis of the sub-group of patients who received one prior
VEGF-TKI-based therapy in the RECORD-1 clinical trial reported a median progres-
sion-free survival of 5.42 months and 1.87 months for the everolimus and BSC-
alone arms, respectively. A Markov model was developed to assess the cost-effec-
tiveness of treating mRCC patients whose disease had failed on one prior VEGF-TKI
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